Department of Cardiac, Thoracic and Vascular Sciences, University of Padova Medical School, Padova, Italy.
Autoimmun Rev. 2013 Jun;12(8):832-4. doi: 10.1016/j.autrev.2012.11.008. Epub 2012 Dec 3.
Triple positivity (positive Lupus Anticoagulant, anticardiolipin and anti β2-glycoptrotein I antibodies) identifies the pathogenic autoantibody (anti Domain I of β2-glycoptroteinI) that is present in patients with definite Antiphospholipid Syndrome (APS). This is supported by the fact that aβ2GPI antibodies obtained by affinity purification in these patients possess LA activity. Moreover, patients and carriers of this profile carry a much higher risk of thrombosis and pregnancy loss than APS patients with positivity for only one of the tests. Thus, very different risk categories exist among patients with APS as well as among carriers of aPL. Clinical studies and interventional trials should first take these high risk subjects into consideration.
三阳性（狼疮抗凝物、抗心磷脂抗体和抗β2-糖蛋白 I 抗体均阳性）可确定存在于明确抗磷脂综合征（APS）患者中的致病性自身抗体（抗β2-糖蛋白 I 结构域 I 抗体）。这一事实得到了以下事实的支持：在这些患者中通过亲和纯化获得的β2GPI 抗体具有 LA 活性。此外，与仅一种检测呈阳性的 APS 患者相比，具有这种特征的患者和携带者发生血栓形成和妊娠丢失的风险高得多。因此，APS 患者以及 aPL 携带者存在非常不同的风险类别。临床研究和干预性试验应首先考虑这些高危人群。
